421 related articles for article (PubMed ID: 36313986)
1. Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions.
Copaescu AM; Ben-Shoshan M; Trubiano JA
Front Med (Lausanne); 2022; 9():923991. PubMed ID: 36313986
[TBL] [Abstract][Full Text] [Related]
2. The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions.
Copaescu A; Mouhtouris E; Vogrin S; James F; Chua KYL; Holmes NE; Douglas A; Slavin MA; Cleland H; Zubrinich C; Aung AK; Goh MSY; Phillips EJ; Trubiano JA;
J Allergy Clin Immunol Pract; 2021 May; 9(5):2010-2015.e4. PubMed ID: 33453452
[TBL] [Abstract][Full Text] [Related]
3. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
4. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
5. Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators.
Chu MT; Chang WC; Pao SC; Hung SI
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672685
[TBL] [Abstract][Full Text] [Related]
6. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
[TBL] [Abstract][Full Text] [Related]
7. Drug Hypersensitivity Reactions.
Wilkerson RG
Immunol Allergy Clin North Am; 2023 Aug; 43(3):473-489. PubMed ID: 37394254
[TBL] [Abstract][Full Text] [Related]
8. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.
Barbaud A; Castagna J; Soria A
Contact Dermatitis; 2022 May; 86(5):344-356. PubMed ID: 35122269
[TBL] [Abstract][Full Text] [Related]
9. Role of in vivo and in vitro Tests in the Diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to Drug.
Bergmann MM; Caubet JC
Curr Pharm Des; 2019; 25(36):3872-3880. PubMed ID: 31696801
[TBL] [Abstract][Full Text] [Related]
10. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
11. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?
Bouvresse S; Valeyrie-Allanore L; Ortonne N; Konstantinou MP; Kardaun SH; Bagot M; Wolkenstein P; Roujeau JC
Orphanet J Rare Dis; 2012 Sep; 7():72. PubMed ID: 23009177
[TBL] [Abstract][Full Text] [Related]
12. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
13. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.
AlJasser MI
Dermatol Res Pract; 2023; 2023():8928198. PubMed ID: 37206671
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
15. Controversies in drug allergy: Testing for delayed reactions.
Phillips EJ; Bigliardi P; Bircher AJ; Broyles A; Chang YS; Chung WH; Lehloenya R; Mockenhaupt M; Peter J; Pirmohamed M; Roujeau JC; Shear NH; Tanno LK; Trubiano J; Valluzzi R; Barbaud A
J Allergy Clin Immunol; 2019 Jan; 143(1):66-73. PubMed ID: 30573342
[TBL] [Abstract][Full Text] [Related]
16. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
17. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
18. [Drug reaction with eosinophilia and systemic symptoms].
Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
[TBL] [Abstract][Full Text] [Related]
19. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
Pavlos R; Mallal S; Ostrov D; Pompeu Y; Phillips E
J Allergy Clin Immunol Pract; 2014; 2(1):21-33. PubMed ID: 24565765
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
